REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1626066
This article is part of the Research TopicMesenchymal Stem Cells and Derived Extracellular Vesicles as Next-Generation Biological Drugs for Tissue RegenerationView all 4 articles
The therapeutic efficacy of mesenchymal stem cells and their extracellular vesicles in the treatment of diverse skin diseases
Provisionally accepted
- Medical University of Bialystok, Bialystok, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The review presents the current knowledge on the potential of mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) in the treatment of various skin diseases such as psoriasis, atopic dermatitis, contact dermatitis, systemic sclerosis, graft-versus-host disease, alopecia areata, systemic lupus erythematosus. The provided review highlighted present the current knowledge on the potential of mesenchymal stem cells (MSCs) and extracellular vesicles (EVs) as a promising therapeutic approach for various skin conditions. promoting tissue regeneration. In addition, it MSCs can modulate the immune response, and release growth factors and cytokines that promote tissue regeneration, healing and reduce inflammation. In turn, exosome's EVs ability to transport various biological molecules, including microRNAs (miRNAs), makes them potential therapeutic agents. Moreover, EVs have been shown to reduce scaling, thickness, and erythema in psoriasis. In atopic dermatitis, EVs can alleviate clinical symptoms, lower serum IgE levels, and reduce immune cell infiltration. Mesenchymal stem cells (MSCs), like bone marrow-derived mesenchymal stem cells (BM-MSCs) exert their immunomodulatory effects by directly targeting various immune cell populations, including T cells, B cells, dendritic cells and natural killer (NK) cells. To fully realize the potential of EVs in clinical practice, further research is needed to: conduct well-designed clinical trials to evaluate the safety and efficacy of EV-based therapies in different skin diseases. Overall, the manuscript suggests that EVs could have the potential to revolutionize the treatment of skin diseases by offering a targeted and effective approach to address various underlying mechanisms, although further large-scale studies are needed.
Keywords: extracellular vesicles, exosomes, mesenchymal stem cells, skin diseases, psoriasis, atopic dermatitis, systemic sclerosis, graftversus-host disease, skin Conceptualization, M.M. and A.M., methodology, M.M., software, M.M., validation, M.M., A.M., H.M., A.C. and I.F., formal analysis, A.M., investigation, M.M., resources, A.M., data curation, M.M.
Received: 09 May 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Matwiejuk, Miklosz, Myśliwiec, Chabowski and Flisiak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mateusz Matwiejuk, Medical University of Bialystok, Bialystok, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.